T-knife: Funding, Investors & Team (Sep 2026)
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
T-knife has raised $176M across 2 funding rounds on record, the most recent a Series B of $110M announced in Aug 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
T-knife Company Profile and Key Stats
Latest funding round on record: Aug 2021.
T-knife Funding Rounds
T-knife raised $66.0M in an undisclosed round announced in Aug 2020.
1 years later, a Series B of $110M was announced in Aug 2021.
T-knife Founders and Leadership Team
No contact details are on record for this team yet.
T-knife Funding Compared to Other Biotechnology Startups
T-knife's latest round of $110M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like T-knife in Biotechnology and Berlin
Companies Similar to T-knife
Computomics applies AI to bioinformatics data to enable rapid understanding of genomics and drive advanced…
smartbax develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug…
Pacifico Biolabs offers fermentation biotechnology for development, production and distribution of…
NanoStruct is a biotechnology company that develops nanostructured sensor chips to identify bacteria and…
Tacalyx, a company originating from Max-Planck-Institute of Colloids and Interfaces in Potsdam, Germany, is…
Primogene is a biotechnology company that provides ingredient development, bioprocess manufacturing, and…
Mbiomics is a company in the field of biotechnology.
At EVANIUM, we make plant compounds like polyphenols and flavonoids more effective by improving their…
Picea Biosolutions is a biotechnology firm. Based on their core platform technology, they develop tailored…
KUPANDO is a pioneering biopharmaceutical firm that is developing TLR 4/7 agonists to boost innate immunity.…
T-knife Funding FAQs
What does T-knife do?
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
How much funding has T-knife raised?
T-knife has raised $176M across 2 rounds on record. The most recent is a Series B of $110M announced in Aug 2021.
When did T-knife last raise funding?
T-knife's most recent funding round on record is a Series B of $110M, announced in Aug 2021.
Who is the CEO of T-knife?
Elisa Kieback is listed as CEO at T-knife.
Where is T-knife headquartered?
T-knife is based in Berlin, Germany.
How many employees does T-knife have?
T-knife is in the 101-250 employee band.
How does T-knife's funding compare to other Biotechnology startups?
T-knife's latest round of $110M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's T-knife Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for T-knife is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.